ARWR
Price
$17.54
Change
+$0.70 (+4.16%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
2.42B
33 days until earnings call
EDIT
Price
$2.86
Change
+$0.32 (+12.60%)
Updated
Jul 8 closing price
Capitalization
239.42M
21 days until earnings call
Interact to see
Advertisement

ARWR vs EDIT

Header iconARWR vs EDIT Comparison
Open Charts ARWR vs EDITBanner chart's image
Arrowhead Pharmaceuticals
Price$17.54
Change+$0.70 (+4.16%)
Volume$47.82K
Capitalization2.42B
Editas Medicine
Price$2.86
Change+$0.32 (+12.60%)
Volume$5.7M
Capitalization239.42M
ARWR vs EDIT Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. EDIT commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and EDIT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (ARWR: $17.54 vs. EDIT: $2.86)
Brand notoriety: ARWR: Notable vs. EDIT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 115% vs. EDIT: 235%
Market capitalization -- ARWR: $2.42B vs. EDIT: $239.42M
ARWR [@Biotechnology] is valued at $2.42B. EDIT’s [@Biotechnology] market capitalization is $239.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 4 bearish.
  • EDIT’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both ARWR and EDIT are a good buy in the short-term.

Price Growth

ARWR (@Biotechnology) experienced а +9.01% price change this week, while EDIT (@Biotechnology) price change was +27.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

EDIT is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.42B) has a higher market cap than EDIT($239M). EDIT YTD gains are higher at: 125.197 vs. ARWR (-6.702). ARWR has higher annual earnings (EBITDA): -68.12M vs. EDIT (-244.52M). ARWR has more cash in the bank: 1.1B vs. EDIT (221M). EDIT has less debt than ARWR: EDIT (31.1M) vs ARWR (388M). ARWR has higher revenues than EDIT: ARWR (545M) vs EDIT (35.8M).
ARWREDITARWR / EDIT
Capitalization2.42B239M1,013%
EBITDA-68.12M-244.52M28%
Gain YTD-6.702125.197-5%
P/E RatioN/AN/A-
Revenue545M35.8M1,522%
Total Cash1.1B221M496%
Total Debt388M31.1M1,248%
FUNDAMENTALS RATINGS
ARWR vs EDIT: Fundamental Ratings
ARWR
EDIT
OUTLOOK RATING
1..100
777
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
5535
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for ARWR (94). This means that EDIT’s stock grew somewhat faster than ARWR’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that EDIT’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (96) in the Biotechnology industry is in the same range as EDIT (99). This means that ARWR’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (35) in the Biotechnology industry is in the same range as ARWR (55). This means that EDIT’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that ARWR’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWREDIT
RSI
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 22 days ago
83%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WHIYX5.95N/A
N/A
Macquarie High Income Fund Class Y
EMAAX15.99N/A
N/A
Gabelli Entpr Mergers & Acquisitions A
FBLEX14.27N/A
N/A
Fidelity Series Stk Selec Lg Cp Val
MRRGX34.98N/A
N/A
Meridian Growth Institutional
AFOIX18.43N/A
N/A
Alger Mid Cap Focus I

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+4.16%
DNLI - ARWR
55%
Loosely correlated
+0.56%
IMNM - ARWR
54%
Loosely correlated
-1.61%
RGNX - ARWR
53%
Loosely correlated
+3.68%
YMAB - ARWR
53%
Loosely correlated
-0.24%
BEAM - ARWR
52%
Loosely correlated
+5.84%
More